AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial
M. Scott Harris(Altimmune (United States)), Barbara S. Fox(Avaxia Biologics (United States)), Theadore Ptak, Emma Erlich(Washington University in St. Louis), Sharon Spence(Avaxia Biologics (United States)), Sally Kennedy(Avaxia Biologics (United States)), Ronald E. Pruitt(Nashville Medical Research Institute), Hartman Deborah(Avaxia Biologics (United States)), Brenda Lemos(Avaxia Biologics (United States)), Séverine Vermeire(KU Leuven)
Cited by 75
Related Papers
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
|New England Journal of Medicine|2006|1k
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study
|The Lancet|2015|779